Association Between Helicobacter Pylori Infection and Vitiligo

Nazia Rashid; Atiya Rahman

doi:10.51253/pafmj.v74i5.9458

Authors

Nazia Rashid Department of Dermatology, Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan
Atiya Rahman Department of Dermatology, Combined Military Hospital Lahore, & CMH Lahore Medical College Lahore, Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i5.9458

Keywords:

Etiology, Helicobacter pylori, Pathogenesis, Vitiligo.

Abstract

Objective: To determine the association between Helicobacter pylori infection and vitiligo in patients visiting a tertiary care hospital of Punjab, Pakistan.

Study Design: Case control study.

Place and Duration of Study: Department of Dermatology, Combined Military Hospital, Lahore Pakistan, from Oct 2021 to Mar 2022.

Methodology: A total of 60 adult vitiligo patients and 60 healthy controls, of both genders, were included in the study. Their ages ranged from 18-70 years. All study participants underwent stool antigen test to detect the presence of Helicobacter pylori antigen.

Results: The mean age of the cases was 43.47±8.16 years whereas it was 40.08±7.42 years in the controls. The mean duration of disease was 4.133±1.21 months. H. pylori Infection was detected in 36(60%) cases as compared to 11(18.3%) controls (p<0.001, OR=6.68); which was found to be statistically significant.

Conclusion: Significant association between H. pylori infection and vitiligo was demonstrated in the current study.

Downloads

Download data is not yet available.

References

Abdelmoneim TA, Aljarbou AN, Alfarouk KO, Alhoufi ST, Ramadan AR, Bashir AH et al. The prevalence of vitiligo variants in association with Helicobacter pylori infection. Am J Dermatol Venereol 2018; 7(1): 1-5.

https://doi.org/10.5923/j.ajdv.20180701.01

Celik E, Atilgan HI, Yalcin H, Onder Z, Celik Y. Relationship between Helicobacter pylori and parapsoriasis. Ann Med Res 2021; 28(5): 1054-1058.

https://doi.org/10.5455/annalsmedres.2021.02.135

Ghotaslou R, Leylabadlo HE, Nasiri MJ, Dabiri H, Hashemi A. Risk of gastric cancer in association with Helicobacter pylori different virulence factors: A systematic review and meta-analysis. Micro Pathogen 2018; 118: 214-219.

https://doi.org/10.1016/j.micpath.2018.03.004

Kutlu Ö, Doğan Z, Ekşioğlu HM, Kekilli M. Relationship between Helicobacter pylori infection and pityriasis versicolor: can Helicobacter pylori infection be a new etiologic factor for pityriasis versicolor? TurkJ Med Sci 2020; 50(4): 771-775.

https://doi.org/10.3906/sag-1910-48

Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol 2020; 38: 621-648. https://doi.org/10.1146/annurev-immunol-100919-023531

Bergqvist C, Ezzedine K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol 2021; 48(3): 252-270.

https://doi.org/10.1111/1346-8138.15743

Çakmak SK, Tantoglu BH, Onan D, Yorulmaz A, Tamer E, Artüz F, et al. The frequency of Helicobacter pylori infection in vitiligo patients. Pigment Int 2015; 2(2): 81.

https://doi.org/10.4103/2349-5847.172775

Doğan Z, Özdemir P, Ekşioğlu M, Filik L. Relationship between Helicobacter pylori infection and vitiligo: a prospective study. Am J Clin Dermatol 2014; 15(5): 457-462.

https://doi.org/10.1007/s40257-014-0087-3

Sanaa A, Bdaiwi MK, Al-Hattab MS, Al-Nafakh A. The frequency of Helicobacter pylori stool antigen in patients with different types of vitiligo in Iraqi Patients. Int J Pharm Res 2017; 9(3): 222-229.

https://doi.org/10.31838/ijpr/2020.sp2.462

Nahhas AF, Braunberger TL, Hamzavi IH. Update on the Management of Vitiligo. Skin Ther Lett 2019; 24(3): 1-6.

Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology 2020; 236(6): 571-592.

https://doi.org/10.1159/000506103.

Solimani F, Meier K, Ghoreschi K. Emerging Topical and Systemic JAK Inhibitors in Dermatology. Front Immunol 2019; 10: 2847.

https://doi.org/10.3389/fimmu.2019.02847

Kim SR, Heaton H, Liu LY, King BA. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy. JAMA Dermatol 2018; 154(3): 370-371.

https://doi.org/10.1001/jamadermatol.2017.5778.

McKesey J, Pandya AG. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo. J Am Acad Dermatol 2019; 81(2): 646–648.

https://doi.org/10.1016/j.jaad.2019.04.032

Illescas-Montes R, Corona-Castro CC, Melguizo-Rodríguez L, Ruiz C, Costela-Ruiz VJ. Infectious processes and systemic lupus erythematosus. Immunology 2019; 158(3): 153-160.

https://doi.org/10.1111/imm.13103

Gravina AG, Priadko K, Ciamarra P, Granata L, Facchiano A, Miranda A, et al. Extra-Gastric Manifestations of Helicobacter pylori Infection. J Clin Med 2020; 9(12): 3887.

https://doi.org/10.3390/jcm9123887

Rifaioğlu EN, Aydoğan F, Bülbül Şen B, Şen T, Ekiz Ö. Investigation into the frequency of Helicobacter pylori infection with carbon 14 urea breath test in patients with vitiligo. Turk J Med Sci 2014; 44(6): 1051-1054.

https://doi.org/10.3906/sag-1309-87

Bakry OA, Basha M, El Hefnawy S, Mekkawy S. Relationship between disease activity and Helicobacter pylori infection in patients with vitiligo. Indian Dermatol Online J 2018; 9:59-61. https://doi.org/10.4103/idoj.IDOJ_77_17

Bashir AH, Yousif SM, Mahmoud MO. Clinico-epidemiological study in Sudanese patients: Prevalence and effect of eradicative triple therapy on extra digestive Helicobacter pylori skin manifestations. Clin Rev Opin 2011; 3 (2): 14-19.

Guarneri C, Ceccarelli M, Rinaldi L, Cacopardo B, Nunnari G, Guarneri F. Helicobacter pylori and skin disorders: a comprehensive review of the available literature. Eur Rev Med Pharmacol Sci 2020; 24(23): 12267-12287.

https://doi.org/10.26355/eurrev_202012_24019